Patents by Inventor Maureen C. Howard

Maureen C. Howard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110165164
    Abstract: Ligands of CCX-CKR2 and the biological role of CCX-CKR2 in cancer is described.
    Type: Application
    Filed: December 9, 2010
    Publication date: July 7, 2011
    Applicant: ChemoCentryx, Inc.
    Inventors: Jennifer M. Burns, Bretton Summers, Maureen C. Howard, Thomas J. Schall, Zhenhua Miao
  • Publication number: 20110052589
    Abstract: Ligands of CCX-CKR2 and the biological role of CCX-CKR2 in cancer is described.
    Type: Application
    Filed: June 11, 2010
    Publication date: March 3, 2011
    Applicant: ChemoCentryx, Inc.
    Inventors: Jennifer M. Burns, Bretton Summers, Maureen C. Howard, Thomas J. Schall
  • Patent number: 7871619
    Abstract: Ligands of CCX-CKR2 and the biological role of CCX-CKR2 in cancer is described.
    Type: Grant
    Filed: August 4, 2004
    Date of Patent: January 18, 2011
    Assignee: ChemoCentryx, Inc.
    Inventors: Jennifer M. Burns, Bretton Summers, Maureen C. Howard, Thomas J. Schall, Zhenhua Miao
  • Patent number: 7777009
    Abstract: Antibodies that bind CCX-CKR2 are described.
    Type: Grant
    Filed: June 19, 2007
    Date of Patent: August 17, 2010
    Assignee: ChemoCentryx, Inc.
    Inventors: Jennifer M. Burns, Bretton Summers, Maureen C. Howard, Thomas J. Schall
  • Publication number: 20090054630
    Abstract: Antibodies that bind CCX-CKR2 are described.
    Type: Application
    Filed: June 19, 2007
    Publication date: February 26, 2009
    Applicant: ChemoCentryx, Inc.
    Inventors: Jennifer M. Burns, Bretton Summers, Maureen C. Howard, Thomas J. Schall
  • Patent number: 7442512
    Abstract: The present invention provides methods for identifying an agent that specifically binds and/or modulates one topology of chemokine receptor but not a second topology of the receptor. Such agents are useful as therapeutics for diseases or conditions associated with a particular chemokine receptor topology. Moreover, the agents are useful for detecting a particular topology of a chemokine receptor, thereby diagnosing disease or predisposition for a disease. In addition, the agents are useful for identifying and isolating cells that express a particular topology of a chemokine receptor.
    Type: Grant
    Filed: September 16, 2002
    Date of Patent: October 28, 2008
    Assignee: ChemoCentryx, Inc.
    Inventors: Jennifer M. Burns, Zhenhua Miao, Zheng Wei, Maureen C. Howard, Brett A. Premack, Thomas J. Schall
  • Patent number: 7413866
    Abstract: The present invention provides methods for identifying an agent that specifically binds and/or modulates one topology of a chemokine receptor but not a second topology of the receptor. Such agents are useful as therapeutics for diseases or conditions associated with a particular chemokine receptor topology. Moreover, the agents are useful for detecting a particular topology of a chemokine receptor, thereby diagnosing disease or predisposition for a disease. In addition, the agents are useful for identifying and isolating cells that express a particular topology of a chemokine receptor.
    Type: Grant
    Filed: May 30, 2003
    Date of Patent: August 19, 2008
    Assignee: ChemoCentryx, Inc.
    Inventors: Jennifer M. Burns, Zhenhua Miao, Zheng Wei, Maureen C. Howard, Brett A. Premack, Thomas J. Schall
  • Patent number: 7253007
    Abstract: Ligands of CCX-CKR2 and the biological role of CCX-CKR2 in cancer is described.
    Type: Grant
    Filed: October 30, 2003
    Date of Patent: August 7, 2007
    Assignee: ChemoCentryx, Inc.
    Inventors: Jennifer M. Burns, Bretton Summers, Maureen C. Howard, Thomas J. Schall
  • Publication number: 20040170634
    Abstract: Ligands of CCX-CKR2 and the biological role of CCX-CKR2 in cancer is described.
    Type: Application
    Filed: October 30, 2003
    Publication date: September 2, 2004
    Applicant: ChemoCentryx, Inc.
    Inventors: Jennifer M. Burns, Bretton Summers, Maureen C. Howard, Thomas J. Schall
  • Publication number: 20040018563
    Abstract: The present invention provides methods for identifying an agent that specifically binds and/or modulates one topology of a chemokine receptor but not a second topology of the receptor. Such agents are useful as therapeutics for diseases or conditions associated with a particular chemokine receptor topology. Moreover, the agents are useful for detecting a particular topology of a chemokine receptor, thereby diagnosing disease or predisposition for a disease. In addition, the agents are useful for identifying and isolating cells that express a particular topology of a chemokine receptor.
    Type: Application
    Filed: May 30, 2003
    Publication date: January 29, 2004
    Applicant: Chemocentryx Inc.
    Inventors: Jennifer M. Burns, Zhenhua Miao, Zheng Wei, Maureen C. Howard, Brett A. Premack, Thomas J. Schall
  • Publication number: 20030124628
    Abstract: The present invention provides methods for identifying an agent that specifically binds and/or modulates one topology of chemokine receptor but not a second topology of the receptor. Such agents are useful as therapeutics for diseases or conditions associated with a particular chemokine receptor topology. Moreover, the agents are useful for detecting a particular topology of a chemokine receptor, thereby diagnosing disease or predisposition for a disease. In addition, the agents are useful for identifying and isolating cells that express a particular topology of a chemokine receptor.
    Type: Application
    Filed: September 16, 2002
    Publication date: July 3, 2003
    Inventors: Jennifer M. Burns, Zhenhua Miao, Zheng Wei, Maureen C. Howard, Brett A. Premack, Thomas J. Schall
  • Patent number: 6207155
    Abstract: Binding compositions and various methods of use of the binding compositions are provided. In particular, a method is provided which comprises administering an effective amount of the binding composition, alone or in combination with other compounds, to eosinophils, thereby reducing the level of eosinophils in an individual. Preferably, the binding composition is a monoclonal antibody specific for CCR3.
    Type: Grant
    Filed: May 6, 1998
    Date of Patent: March 27, 2001
    Assignee: Schering Corporation
    Inventors: J. Christopher Grimaldi, Maureen C. Howard, Robert L. Coffman